Evidence map›Paper›PMID 38163881›Full record

ArticleJournal of experimental & clinical cancer research : CR2024

EIF4A3-mediated biogenesis of circSTX6 promotes bladder cancer metastasis and cisplatin resistance.

Wenjie Wei, Kan Liu, Xing Huang, Shuo Tian, Hanfeng Wang, Chi Zhang, Jiali Ye, Yuhao Dong, Ziyan An, Xin Ma and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Wenjie Wei *Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
Kan Liu *Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
Xing Huang *Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
Shuo TianDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
Hanfeng WangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
Chi ZhangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
Jiali YeDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
Yuhao DongDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
Ziyan AnDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
Xin MaDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
Baojun WangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China. baojun40009@126.com.
Yan HuangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China. dr.huangyan301@foxmail.com.
Xu ZhangDepartment of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China. xzhang301@163.com.ORCID http://orcid.org/0000-0002-6908-6768
Chinese PLA General Hospital · CN

Funding

National Natural Science Foundation of China 81972389National Natural Science Foundation of China 82103594National Natural Science Foundation of China 82372704
6 · The paper itself

Abstract

backgroundCisplatin (CDDP)-based chemotherapy is a standard first-line treatment for metastatic bladder cancer (BCa) patients, and chemoresistance remains a major challenge in clinical practice. Circular RNAs (circRNAs) have emerged as essential regulators in carcinogenesis and cancer progression. However, the role of circRNAs in mediating CDDP chemosensitivity has yet to be well elucidated in BCa.

methodsCircSTX6 (hsa_circ_0007905) was identified by mining the public circRNA datasets and verified by Sanger sequencing, agarose gel electrophoresis, RNase R treatment and qRT-PCR assays. Then, function experiments were performed to evaluate the effects of circSTX6 on BCa metastasis. Luciferase reporter assay, RNA pull-down, RNA immunoprecipitation (RIP), RNA stability assay, Fluorescence in situ hybridization (FISH) and Immunofluorescence (IF) were conducted to evaluate the interaction among circSTX6, miR-515-3p, PABPC1 and SUZ12. Animal experiments were performed to explore the function of circSTX6 in tumor metastasis and CDDP sensitivity.

resultsWe identified that circSTX6 was significantly upregulated in clinical samples and cells of BCa. Functionally, circSTX6 promoted cell migration and invasion both in vitro and in vivo. Mechanistically, circSTX6 could act as a miR-515-3p sponge and abolish its effect on SUZ12. Moreover, circSTX6 was confirmed to increase the stability of SUZ12 mRNA by interacting with a mRNA stabilizer PABPC1 and subsequently promote the expression of SUZ12. Importantly, silencing of circSTX6 improved the chemosensitivity of CDDP-resistant bladder cancer cells to CDDP. Furthermore, in vivo analysis supported that knockdown of circSTX6 attenuated CDDP resistance in BCa tumors.

conclusionThese studies demonstrate that circSTX6 plays a pivotal role in BCa metastasis and chemoresistance, and has potential to serve as a therapeutic target for treatment of BCa.

Indexed as

MicroRNAsUrinary Bladder NeoplasmsAnimalsCell Line, TumorCell ProliferationCisplatinDEAD-box RNA HelicasesEukaryotic Initiation Factor-4AGene Expression Regulation, NeoplasticHumansIn Situ Hybridization, FluorescenceRNA-Binding ProteinsRNA, CircularRNA, MessengerCisplatinDEAD-box RNA HelicasesEIF4A3 protein, humanEukaryotic Initiation Factor-4AMicroRNAsMIRN515 microRNA, humanRNA-Binding ProteinsRNA, CircularRNA, MessengerBladder cancerCDDPcircSTX6miR-515-3pPABPC1SUZ12

Identifiers

PMID38163881
PMCPMC10759346
OpenAlexW4390499072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.